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’INTRODUCTION
Scaﬀold diversity is one of many parameters that may be used
to characterize compound screening libraries.
1 The balance
between the diversity of scaﬀolds within a library and the density
ofcoverageforeachscaﬀoldvariesaccordingtothelibrarydesign
principles applied. Dense representation over small numbers of
scaﬀolds is often applicable in libraries focused on a particular
biological target class where thorough coverage of pharmaco-
phore space is desired, for example in kinase-focused libraries.
2
However, such dense coverage of scaﬀold space may impart
signiﬁcant redundancy due to over population with structurally
similar compounds. However, sparse representation of a large
number of scaﬀolds may also be problematic in a screening
library; for example, hit conﬁrmation and rapid generation of
structureactivityrelationshipsischallengingforcompoundsthat
are single exemplars of a particular scaﬀold. Thus the balance
between scaﬀold diversity and scaﬀold representation is an
important feature in library design and use.
In order to analyze the scaﬀold diversity of a compound
library, a suitable representation of a scaﬀold is required. The
deﬁnition of a scaﬀold often depends on the problem and the
expertise of the individual deﬁning the scaﬀold. One frequently
applied description of a scaﬀold is the Markush structure, which
ﬁrst appeared in a patent, ﬁled by Eugene A. Markush of the
Pharma-Chemical Corporation in 1924.
3 The patent claimed a
family of pyrazolone dyes and described a scaﬀold structure
appended with “R” groups to denote the substitution patterns
(Figure 1). Markush structures are generic and use variables to
encode more than one structure in a single representation.
Markush structures are often used in patent applications to
deﬁne the scope of a chemical series.
4 However, Markush
structures often diﬀer from how a medicinal chemist would
deﬁne the relevant scaﬀold of a chemical series. A scaﬀold may,
for example, deﬁne the core structure essential for pharmacolo-
gicalactivityandtheappendedsubstituentvectorsdeﬁneoptimal
substitution patterns. For example, the HSP90 inhibitor NVP-
AUY922 (Figure 2a)
5 is represented by a Markush structure
(Figure 2b) in the corresponding patent application.
6 A medic-
inal chemistry representation of the scaﬀold may be more
granular (Figure 2c) to reﬂect the importance of the resorcinol
and isoxazole amide functionalities for pharmacological activity
as well as the benzylic amine substituent for aqueous solubility.
5
A preferred scaﬀold representation is objective, invariant, and
is not data set dependent.
7 One such method is the Murcko
framework, proposed by Bemis and Murcko in 1996 which has
been used to analyze the structures of known drugs.
8 The
method dissects molecules into ring systems (Figure 2d), linkers
(Figure 2e), side chain atoms (Figure 2f), and the framework
(Figure 2g), which is the union of ring systems and linkers in a
molecule. A Murcko framework (Figure 2h) retains information
onatomtype,whereasagraphframework
8(Figure2i)reducesall
atoms to carbon and all bonds to single bonds.
Thereareexamplesofmethodswherethescaﬀolddeﬁnitionis
data set dependent, such as a Maximum Common Substructure
(MCS)search.Inthisapproach,moleculesaretypicallyclustered
Figure1. AninterpretationoftheMarkushstructureasdescribedinthe
1924 Markush patent.
3
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based upon their chemical ﬁngerprints and for each cluster the
MCS is found: the compounds are then grouped based upon
their MCS.
9 This method is data set dependent since diﬀerent
compound data sets will result in a diﬀerent cluster assignment
and therefore a diﬀerent MCS.
The Murcko framework of a molecule can also be dissected
intomorethanoneringsystembycleavinglinkerbondsbetween
rings in the Murcko framework. Compound libraries have been
analyzed by the ring systems present,
10 which can be arranged in
a hierarchical tree according to complexity.
11,12 The Scaﬀold
Tree
13 is such an example of a hierarchical tree of ring systems.
The Scaﬀold Tree methodology takes each molecule in a library
and iteratively removes rings one by one, based on a set of
prioritization rules, until only one ring remains. Each molecule
has n+1 Levels numbered sequentially from Level 0 (the single
remaining ring) up to Level n (the whole molecule) where Level
n-1 is the Murcko framework (Figure 2j). The scaﬀold hierar-
chies of each molecule are then combined into a tree for the
whole library. The Scaﬀold Tree has been used in conjunction
with biochemical activity data for structureactivity relationship
(SAR)analysis
1417but,toourknowledge,hasnotyetbeenused
forascaﬀolddiversityanalysisofcompoundlibraries,basedupon
the number and frequency of scaﬀolds present, as described
herein.
A number of studies have been carried out to investigate the
diversityofcompoundsetsbaseduponthefrequencyofscaﬀolds
present. For example, Bemis and Murcko identiﬁed 1179 scaf-
folds present in 5129 known drugs using the Murcko framework
deﬁnition of a scaﬀold.
8 Half of the drugs in the data set were
based on the 32 most frequently occurring scaﬀolds, suggesting
Figure 2. The HSP90 inhibitor NVP-AUY922 depicted using diﬀerent scaﬀold representations.2176 dx.doi.org/10.1021/ci2001428 |J. Chem. Inf. Model. 2011, 51, 2174–2185
Journal of Chemical Information and Modeling ARTICLE
that the scaﬀold diversity of known drugs is extremely low.
A similar analysis of the CAS (Chemical Abstracts Service)
Registry of over 24 million compounds also showed that a large
percentageoforganiccompoundsarerepresentedbyonlyasmall
percentage of scaﬀolds.
18 These ﬁndings suggest that the more
frequentlyascaﬀoldhasbeenused,themorelikelyitwillbeused
again.Asimilarconclusionisdrawnfromastudythatlooksatthe
co-occurrence of fragments in the same molecule.
19 It was found
thatparticularfragmentsandcombinationsoffragmentswerefar
more frequent than othersandwere therefore termed “Chemical
Clich  es”.
19
Compound libraries have also been analyzed in terms of the
topology of the scaﬀolds present. One study describes ring systems
present in the CAS Registry using three integer descriptors to
represent the topology of the ring system, therebyallowing the ring
systems to be plotted in 3-dimensional topology space.
20 Some
areasoftopologyspacewerehighlypopulatedwithsigniﬁcantvoids
also observed. A subset of the CAS Registry ﬂagged for “Ther-
apeutic Use” was mapped onto the topology space to represent
medicinally relevant rings. Two bounds were found that contain
these medicinally relevant rings, namely size and molecular com-
plexity; indicating that the scaﬀold space of medicinally relevant
rings is inﬂuenced by size constraints for druglike molecules and
ease of synthesis. Similar conclusions were reached in a study that
enumerated graph representations of scaﬀold topologies and ex-
amined frequency of occurrence in compound libraries.
21
An analysis of the scaﬀolds present in a set of approximately
150,000 bioactive compounds found only 780 simple aromatic
scaﬀolds.
22 A virtual library containing nearly 600,000 small
aromatic scaﬀolds was produced to assess how the biologically
active scaﬀolds covered chemical space. The scaﬀolds were
clustered in a Self-Organizing Map (SOM) which demonstrated
that biologically active scaﬀolds are sparsely distributed across
the virtual library forming well-deﬁned activity islands. The
authors suggest three possible reasons for the lack of diversity
of bioactive molecules:
1 Biologicalactivityislimitedtoasmallareaofchemicalspace;
2 Most small aromatic scaﬀolds are synthetically inaccessible;
3 The chemical space of small aromatic scaﬀolds is so large
that known bioactive compounds will only ever cover an
insigniﬁcant proportion of this space.
A similar investigation
23 also suggested that some scaﬀolds are
more popular due to the synthetic ease of attaching other medicin-
ally relevant moieties; the accumulated synthetic and medicinal
chemistry knowledge on these more popular scaﬀolds makes them
more attractive for future use. A further study identiﬁed scaﬀolds
that have selectivity for target-gene families but ﬁnds that these
scaﬀolds are underrepresented in approved drugs.
24
Metrics have been applied to quantify the distribution of mole-
culesoverscaﬀolds.ForexampleNC50CandPC50Cquantifythe
number of scaﬀolds and the percentage of scaﬀolds that represent
50% of molecules in a library.
23 Studies using these metrics again
showthatthe distribution of moleculesoverscaﬀolds is skewed in
compound libraries.
25 S h a n n o ne n t r o p ym a ya l s ob eu s e dt o
describe the distribution of molecules over scaﬀolds. A Shannon
entropyof0indicatesthatallcompoundscontainthesamescaﬀold;
a high Shannon entropy indicates that each scaﬀold represents the
same number of molecules and that the library is, therefore, evenly
distributed over the represented scaﬀolds.
26
The studies discussed above highlight the lack of scaﬀold
diversityinmanycompoundlibraries.RecentlyPittetal.generated
a collection of 24,847 virtual small aromatic rings named VEHI-
CLe (virtual exploratory heterocyclic library).
27 Only 1701 of the
VEHICLe ring systems were identiﬁed as synthesized (i.e.i n
existence). A machine learning approach predicted that over
3000oftheringsystemscouldeasilybesynthesized.Thissuggests
that only a small area of scaﬀold space is covered by synthesized
compounds and that a large area of scaﬀold space is synthetically
accessible.
Inthisworkweanalyzethescaﬀolddiversityof7representative
compound libraries, including the ChEMBLdb, drug sets, vendor
libraries, and in-house screening collections. We compare the
Murcko framework and Scaﬀold Tree representations of scaﬀolds
fortheﬁrsttimeandshowthatLevel1oftheScaﬀoldTreeisuseful
for the characterization of scaﬀold diversity in compound libraries
and oﬀers advantages over the use of Murcko frameworks. This
analysis also demonstrates that the majority of compounds in
the libraries we analyzed contain only a small number of well
represented scaﬀolds and that a high percentage of singleton
scaﬀolds represents the remaining compounds. Tree Maps have
recently been exempliﬁed as a useful method for the two-dimen-
sional (2D) depiction of structure activity relationships using
dendrograms which incorporate molecule fragmentation
hierarchies.
28 Here we demonstrate the use of Tree Maps to
visualize the distribution of molecules over scaﬀolds, and the
molecular similarity of the scaﬀolds, within a compound library.
This novel use of Tree Maps provides easily interpretable depic-
tions of compound library scaﬀold diversity for the medicinal
chemistry community.
’METHODS
Data Sets. The scaffold diversity analyses were performed on
7 data sets containing both publicly available and proprietary
compounds.TheyaredescribedhereandsummarizedinTable1.
ICR Screening Collection (ICRSC). 79,742 Compounds from
the Institute of Cancer Research (ICR) in-house hit discovery
screening collection. This collection includes compounds se-
lected from multiple commercial vendors based upon in-house
developed filters for leadlike molecules as well as compounds
synthesized in-house.
Table 1. Summary of the Data Sets Used in the Scaﬀold
Diversity Analysis
data set description compounds
ICRSC compounds from the ICR’s
internal screening collection
79,742
VC compounds from the ICR’s
preferred vendors
1,923,627
ICRFL fragments from the ICR’s internal
screening collection
2448
CHEMBL compounds from the EBI’s
ChEMBL database. The CHEMBL
database compounds are taken
from the medicinal chemistry literature.
31
530,038
DBSM small molecule drugs taken from
DrugBank
34
4654
DBAD approved drugs taken from DrugBank
34 1361
BIOFOC compounds from BioFocus
designed to target kinases
35
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Vendor Collection (VC). 1,923,627 Compounds that are
commercially available from 11 of the ICR’s preferred vendors.
Compoundlibrariesweredownloadeddirectlyfromthevendors,
and compounds containing toxicophores were removed. Mol-
ecules with more than 35 heavy atoms or an AlogP greater than
6 were also removed.
29
ICR Fragment Library (ICRFL). The fragment library
(ICRFL) contains 2448 fragments, either synthesized at the
ICR or purchased from vendors. [Fragment definition para-
meters: molecular weight: 150300 Da (+20 Da for specific
groups),AlogP:e3,H-bondacceptors:e5,H-bonddonors:e
3, topological polar surface area (TPSA): e 75 Å
2, rotatable
bonds:e4,heavyatoms:g10,rings:13,ringsize:37atoms,
fusedrings:e2,numberofsulfuratoms:e1,numberofhalogen
atoms: e 1 (except fluorine), compounds containing toxico-
phores were removed.]
ChEMBLdb (CHEMBL). 530,038 Compounds from the EBI-
ChEMBLdatabase.ChEMBL-dbconsistsofbioactivecompounds
taken from the medicinal chemistry literature and is manually
curated by the EBI-ChEMBL team.
30 CHEMBL represents
80% of the version (08) of ChEMBLdb, Version 03 was used in
this work.
31
DrugBank. DrugBank is a bioinformatics and chemoinfor-
matics resource that combines chemical drug data with target
drugdata.Itcontains smallmolecule drugs, FDAapprovedsmall
molecule and biotech (protein/peptide) drugs, experimental
drugs, and the protein or drug target sequences related to these
drugs.
32,33 DrugBank Small Molecules (DBSM) contains 4654
small molecule drugs from DrugBank version 2.5, 1335 of which
are also contained in DrugBank Approved Drugs (DBAD).
34
DrugBank Approved Drugs (DBAD) contains 1361 approved
drugs from Drug Bank version 2.5.
34
BioFocus Kinase Focused Library (BIOFOC). Library of
10,000 compounds from BioFocus designed to target kinases.
35
Scaffold Representations. To analyze the scaffold diversity
of the 7 data sets, two scaffold representations were used:
Murcko frameworks
8 and the Scaffold Tree
13 both of which
represent compounds containing cyclic systems. Murcko frame-
works were generated in Pipeline Pilot 7.0
36 using the Generate
Fragments component with the FragmentsToGenerate parameter
set to MurckoAssemblies; all other parameters were kept as the
default values.
The Scaﬀold Tree
13 is a hierarchical classiﬁcation of chemical
scaﬀolds. Murcko frameworks of the compounds in the library
are generated; these are leaf nodes of the Scaﬀold Tree. Lower
levels of the Scaﬀold Tree are obtained by iterative removal of
ringsaccordingtoasetofprioritizationrulesthataredesignedto
retain the most richly functionalized ring systems and are
intended to be intuitive to a synthetic medicinal chemist. This
process continues until only one ring remains.
13 We have
observed that, in the majority of cases, the most richly function-
alizedringsystemisretained;however,incompoundscontaining
an all carbon fused ring system, this scaﬀold is prioritized over a
single ring heterocycle in the same molecule which could be
regardedas more richly functionalized.Theroot node, the single
remaining ring after fragmentation, is named Level 0, and sub-
sequent levels or nodes in the tree are named numerically
(Figure 2j). There can be any number of levels to the Scaﬀold
Tree depending on the complexity of the molecules represented.
Compounds of diﬀerent complexity have diﬀerent numbers of
Levels in the Scaﬀold Tree; therefore, we sought a Level that the
majority of compounds in our representative data set possess. All
compoundsoftheScaﬀoldTreepossessLevel0;however,Level0
always contains a single nonfused ring and is too generic to be a
useful scaﬀold representation; for example, many molecules are
reduced to the same single ring representation which lacks
suﬃcientgranularity.HigherlevelsoftheScaﬀoldTreewereclose
or identical to the Murcko framework which often incorporates
multiple ring systems. We observed fewer examples of concor-
dance to the Murcko framework at Level 1 than at all other levels
(excluding Level 0) although Level 1 scaﬀolds can be the same as
the Murcko framework, for example, in the case of compounds
deﬁned as fragments. Level 2 scaﬀolds and above have a greater
number of examples where the scaﬀold is the sameas the Murcko
framework. In addition, some small compounds (e.g. fragments)
donotpossessaLevel2orabove.WethereforeusedLevel1ofthe
Scaﬀold Tree in our analysis. In summary, the Scaﬀold Tree is a
data set independent, rule based method, which is designed to
retainthemostrichlyfunctionalizedringsystems.Level1scaﬀolds
containoneortworings,andasLevel1islesscomplexthanhigher
levels of the Scaﬀold Tree, the vast majority of compounds in our
representativedatasetspossessaLevel1scaﬀold;onlysinglerings
with no substituents are excluded from Level 1 (see below).
The Molecular Operating Environment (MOE) from the
Chemical Computing Group
37 was used to generatethe Scaﬀold
Tree for each data set using the linear fragmentation function. An
SVL script was applied to an SDF ﬁle; the linear fragmentation
functionwasusedtoapplytheScaﬀoldTreefragmentationrules.
The Level 1 scaﬀold of each compound is saved to a molecular
database (.mdb ﬁle) along with the original molecule.
As mentioned above, both Level 1 scaﬀolds and Murcko
frameworks can only represent molecules containing ring sys-
tems; therefore, acyclic molecules are omitted from the data
analysis. This does not aﬀect the ICRFL and BIOFOC data sets;
for ICRSC, VC, and CHEMBL, between 0.06% and 2% of
compounds are excluded. For DBSM and DBAD, 17.3% and
7.6% of molecules are excluded which include, for example,
acyclic peptide drugs or development compounds. Molecules
containing only a single ring with no substituents have one level,
Level 0 of the Scaﬀold Tree, and are, therefore, omitted from the
analysis. This only aﬀects the VC, CHEMBL, and DBSM data
setswherelessthan0.15%ofcompoundsaresingleringswithno
substituents. One of the Scaﬀold Tree rules is the removal of
3-membered ring heterocycles (e.g. epoxides). The 3-membered
ring is converted to a double bond. This step is carried out when
side chains are removed from the molecule, before the iterative
removal of other rings. As a consequence, compounds that
contain only 3-membered heterocyclic rings are renderedacyclic
before the iterative removal of rings and are therefore excluded
from the analysis. This only aﬀects the VC, CHEMBL, DBSM,
and DBAD data sets where this rule applies to less than 0.5% of
compounds.
Scaffold Diversity Analysis. In these analyses we investigate
two types of diversity: the distribution of molecules over the
unique scaffolds present in the data set and the structural
diversity of these scaffolds. Of the methods described below,
the scaffold counts and cumulative scaffold frequency plots
provide information on the distribution of molecules over
scaffolds, and the Tree Maps provide information on both the
distribution and structural diversity.
Scaffold Counts. The scaffold diversity analysis was per-
formed on the ICRSC, VC, ICRFL, CHEMBL, DBSM, DBAD,
andBIOFOCdatasets.ForeachdatasettheMurckoframeworks
andLevel1oftheScaffoldTreeweredefinedforeachcompound2178 dx.doi.org/10.1021/ci2001428 |J. Chem. Inf. Model. 2011, 51, 2174–2185
Journal of Chemical Information and Modeling ARTICLE
and the following steps performed using Pipeline Pilot.
36 The
numbers of unique Murcko frameworks and Level1 scaffolds for
each data set were counted, along with the number of molecules
they represent; this is referred to as the scaffold frequency. The
number of singleton scaffolds was also recorded; singleton
scaffolds are scaffolds that are only present in one exemplar
molecule.
Cumulative Scaffold Frequency Plots (CSFP). Scaffold fre-
quency is the number of molecules that contain a particular
scaffold; the scaffold frequency can be represented as a percen-
tageof totalmoleculesin thedata set. To generatecumulative
scaffold frequency plots (CSFP), the scaffolds are sorted by
their scaffold frequency (most frequent to least frequent) the
cumulative percentage of scaffolds is then plotted against the
cumulative scaffold frequency as a percentage of total mol-
ecules. CSFPs were generated for each data set using both the
Murcko and Level 1 scaffold representations. From the
cumulative frequency plots, the percentage of scaffolds that
represent n percent of compounds can be determined Pn.F o r
example P50 is the percentage of scaffolds that represent 50%
of compounds; this measure has been used in various scaffold
diversity analyses and is often termed PC50C.
23 The ratio of
scaffolds to compounds (N/M) and the ratio of singleton
scaffolds to all scaffolds (Ns/N) are also used to assess the
diversity of scaffold space.
Tree Maps. Tree Maps are visualizations of hierarchical data
structures and were introduced in 1992 by Shneiderman to
visualize the directory tree of hard disks.
38 Tree Maps use a 2D
space-filling approach where rectangles or circles represent each
leaf of a hierarchical tree. The size and color of each rectangle or
circle can correspond to specific properties of the data being
represented. Tree Maps have been used previously to visualize
hierarchical clusters of compounds and their biological activity
data.
28,39 Rather than visualizing the whole hierarchical Scaffold
Tree with Tree Maps we have visualized all Level 1 scaffolds
presentineachdatasetandhaveclusteredthescaffolds basedon
their structural similarity. We have used circular Tree Maps
rather than rectangular Tree Maps to better highlight clusters of
scaffolds.The colorandarea of thecircles represents thescaffold
frequency of the scaffolds they represent. This allows visualiza-
tion of both scaffold structural diversity and the distribution of
compounds over scaffolds. To our knowledge this is the first
application of Tree Maps to visualize the distribution and
chemical diversity of compound libraries.
Tree Maps were created using the software TreeMap from
MacroFocus.
40 First, the Level 1 scaﬀolds of each data set were
clustered using FCFP_2 ﬁngerprints. The Cluster Molecules
component in Pipeline Pilot was applied with the average
number of compounds per cluster set to 20. This component
selects a molecule from the data set at random as the ﬁrst cluster
center and then selects the remaining cluster centers to give
maximum dissimilarity to the ﬁrst cluster center and each other.
The remaining molecules are then assigned to each cluster based
upon their similarity to the cluster center. This method is order
dependent, as the random molecule selection is dependent on
the order the molecules enter the component. As the Cluster
Molecules component presorts the data we used the Cluster Data
component to test the order dependency of the clustering
algorithm. The clustering protocol was applied 5 times; for each
run, a random number was generated for each compound using
the current time in 24-h format as the seed for the Random
Number component. The compounds were then sorted by the
random number and sent to the Cluster Data component. Thus,
for each run, the compounds are entering the Cluster Data
component in a diﬀerent order. For each run of the protocol
the mean Kelley spread and distance of the clusters were
calculated.
41,42 The spread is based on the mean pairwise
similarity of the members of a cluster, and the distance reﬂects
how dissimilaroneclusterisfromanother.The meanspreadand
distance for each of the 5 runs were consistent, within one
standard deviation, when tested with all 7 data sets. In summary,
the order dependency of the Cluster Molecules component did
not have a major eﬀect on the clusters used to visualize the data
sets in the Tree Maps.
After clustering, each scaﬀold had a cluster number attributed
to it which could be used in the TreeMap software to group the
scaﬀoldsbasedontheclusterstowhichtheybelong.Thescaﬀold
frequency attributed to each scaﬀold was also used in the
visualization.
In the Tree Maps, scaﬀolds are represented by circles where
the area of the circle is proportional to the scaﬀold frequency.
The color of the circle is also related to the scaﬀold frequency.
The scaﬀolds are grouped into gray circles, which represent the
cluster towhich theybelong.The distancesbetweenclusters and
scaﬀoldsintheTreeMapsarenotrepresentativeofthestructural
or property similarity of clusters and scaﬀolds.
’RESULTS AND DISCUSSION
Scaffold Counts. Tables 2 and 3 show the number of
compounds included in the analysis (M) and the number of
MurckoframeworksandLevel1scaffoldspresentineachdataset
(N) as well as the number of singleton scaffolds (Ns). The ratios
of scaffolds to molecules (N/M) and singleton scaffolds to total
scaffolds (Ns/N)arealsoreported. Pnvalues (P25,P50,andP75in
Tables 2 and 3) indicate the percentage of scaffolds that
represent n percent of compounds; thus P75 is the percentage
of scaffolds that represent 75% of all compounds in the data set.
The significance of these figures is discussed alongside the
cumulative scaffold frequency plots below.
When analyzed using Level 1 scaﬀolds, the BIOFOC and VC
data sets have an extremely low ratio of scaﬀolds to molecules
(N/M = 0.02 and 0.04, respectively) indicating that these data
sets contain heavily represented scaﬀolds. The CHEMBL and
ICRSC data sets also have a low proportion of scaﬀolds (N/M =
0.13 and 0.16, respectively). The DBAD, DBSM, and ICRFL
Table2. MurckoFrameworkAnalysis:ResultsoftheScaﬀold
Diversity Analysis on the ICRSC, VC, ICRFL, CHEMBL,
DBSM, DBAD, and BIOFOC Data Sets Using Murcko
Frameworks
a
data set MN N s N/MN s/NP 25 P50 P75
ICRSC 76,563 33,050 23,123 0.41 0.70 1.23 9.93 39.8
VC 1,922,434 388,952 237,617 0.20 0.61 0.22 2.01 15.3
ICRFL 2448 1146 822 0.47 0.72 1.67 12.0 46.6
CHEMBL 519,362 153,199 102,548 0.29 0.67 0.49 4.49 24.1
DBSM 3849 2061 1680 0.54 0.82 1.05 12.6 53.3
DBAD 1258 785 633 0.57 0.81 3.58 19.9 59.9
BIOFOC 10,000 2498 1559 0.25 0.62 0.80 5.36 20.9
aM = number of compounds, N = number of Murcko frameworks, Ns =
numberofsingletonscaﬀolds,Pn=percentageofscaﬀoldsthatrepresent
n percent of compounds.2179 dx.doi.org/10.1021/ci2001428 |J. Chem. Inf. Model. 2011, 51, 2174–2185
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datasets(N/M=0.55,0.52,and0.43,respectively)have closeto
onescaﬀoldforeverytwomoleculessuggestingtheyarethemost
scaﬀold diverse data sets. The ratioof scaﬀolds to molecules (N/
M) should be used in conjunction with the number of singleton
scaﬀolds to provide accurate information on the distribution of
molecules over scaﬀolds. For example, DBSM has N/M = 0.52
(i.e. there are 1.9 molecules to every scaﬀold) suggesting that the
data set is scaﬀold diverse. However, the proportion of singleton
scaﬀolds to scaﬀolds (Ns/N) is 0.83; therefore, 83% of scaﬀolds
(1670 scaﬀolds) represent only 1 molecule each, and 17% of
scaﬀolds(342scaﬀolds)representtheremaining2173molecules
(an average of 6.3 molecules per scaﬀold). Table 3 indicates that,
in most cases, a large proportion of the Level 1 scaﬀolds are
singletons (Ns/N > 0.6), suggesting that the distribution of
molecules over scaﬀolds is uneven. Anexception is the BIOFOC
data set (Ns/N = 0.35); despite having the lowest proportion of
scaﬀolds (N/M =0.02),a low proportion of these are singletons.
In the case of the BIOFOC data set the molecules are more
evenly distributed over a small number of scaﬀolds. This result is
expectedsince the BIOFOCdataset was designed as a screening
collection containing a selection of kinase inhibitor scaﬀolds that
are equally represented.
35
The Murcko framework analysis delivers similar overall con-
clusions(Table2).BIOFOCandVChavethelowestproportion
of scaﬀolds (N/M= 0.25 and 0.20, respectively), and DBAD,
DBSM, and ICRFL have the highest proportion of scaﬀolds
(N/M = 0.57, 0.54, and 0.47, respectively). A high proportion of
scaﬀolds are singletons (Ns/N > 0.6), and Ns/N values are more
uniform across the 7 data sets than for the Level 1 scaﬀold
analysis. One diﬀerence in the analyses using Murcko frame-
works and Level 1 scaﬀolds is the proportions of scaﬀolds to
molecules (N/M). The lowest proportion of scaﬀolds when
using the Murcko framework representations (for VC N/M =
0.20)ishigherthanthelowestproportionofscaﬀoldswhenusing
Level1scaﬀoldrepresentations(forBIOFOCN/M=0.02).The
range of proportions is also narrower for Murcko frameworks
(range of N/M = 0.37) compared to Level 1 scaﬀolds (range of
N/M = 0.53). Murcko frameworks are a more discriminating
representation of a scaﬀold (i.e. they carry greater chemical
description) than Level 1 Scaﬀolds, and, therefore, more unique
scaﬀolds are deﬁned by Murcko frameworks. Thus, there is a
higher proportion of Murcko scaﬀolds present in data sets. The
diﬀerence in N/M for the Murcko and Level 1 analyses are
signiﬁcant for most cases examined apart from ICRFL, DBSM,
and DBAD where the diﬀerence is very small (Table 4). A
possible reason is that these three data sets contain a relatively
highpercentageofmoleculeswhichhaveonering(12.519.4%)
as deﬁned in Pipeline Pilot
36 (Table 4). In the case of molecules
containing a single ring, Level 0 of the Scaﬀold Tree is this single
ringandisalsotheMurckoframework,whereasthenextLevelup
the hierarchical Scaﬀold Tree (Level 1) is the single ring plus its
substituents (the whole molecule). For such compounds, the
Level 1 scaﬀold is more descriptive than the Murcko framework,
and, therefore, more unique Level 1 scaﬀolds than Murcko
frameworks are generated. The ICRFL, DBSM, and DBAD data
sets have a much higher proportion of fragmentlike compounds
containing only one ring than other data sets in our analysis and
could, we propose, explain why the results for the Murcko and
Level 1 analyses for these data sets are more similar.
In summary, we have shown that the proportion of scaﬀolds
present in a data set (N/M), in conjunction with the proportion
of singleton scaﬀolds (Ns/N), is a useful indicator of scaﬀold
diversityacrossadiverserange of compound libraries.Inmostof
the data sets tested, molecules are unevenly distributed, with a
smallnumberofhighlypopulatedscaﬀoldsandalargenumberof
singletons. Murcko frameworks are a more discriminating re-
presentation of a scaﬀold than Level 1 scaﬀolds, and, as a result,
more unique scaﬀolds are deﬁned by Murcko frameworks. For
molecules containing one ring, Level 1 scaﬀolds provide a more
granular representation in comparison to Murcko scaﬀolds.
Cumulative Scaffold Frequency Plots (CSFP) and Pn Values.
The CSFPs are shown in Figure 3 for the Level 1 scaffolds and
Figure 4 for the Murcko frameworks. The CSFPs give an indica-
tion of the distribution of molecules over scaffolds. In the
extreme case where each scaffold represents the same number
of compounds, the plot would be diagonal from (0%, 0%) to
(100%, 100%); therefore, the closer the curve is to the diagonal,
the more evenly distributed the data set.
In the case of Level 1 scaﬀolds (Figure 3) the CSFPs give
similarconclusionstothe proportion of scaﬀoldstomolecules as
shown in Table 3. DBAD, DBSM, and ICRFL are closest to the
diagonal, indicative of a more even distribution. The BIOFOC,
VC, CHEMBL, and ICRSC data sets are furthest from the
diagonal and are least evenly distributed. All curves begin with
a very steep gradient; this indicates the presence of scaﬀolds that
representalargeproportionofthedataset.Theshallowregionof
the curve represents the high proportion of singleton scaﬀolds.
An interesting example is the BIOFOC data set, which has
a much lower ratio of singleton scaﬀolds to overall scaﬀolds
(Ns/N = 0.35) despite having a low proportion of scaﬀolds
overall (N/M = 0.02). This proﬁle is represented by a lower
gradient early in the plot compared to other data sets (VC,
CHEMBL, and ICRSC, Tables 2 and 3). The BIOFOC curve
Table 3. Scaﬀold Tree Analysis: Results of the Scaﬀold
Diversity Analysis on the ICRSC, VC, ICRFL, CHEMBL,
DBSM, DBAD, and BIOFOC Data Sets Using Level 1 of the
Scaﬀold Tree
a
data set MN N s N/M Ns/N P25 P50 P75
ICRSC 79,563 12,520 8637 0.16 0.69 0.22 1.34 7.70
VC 1,922,433 81,368 62,889 0.04 0.77 0.026 0.14 0.70
ICRFL 2448 1074 792 0.43 0.74 2.04 10.1 43.0
CHEMBL 519,341 68,370 53,385 0.13 0.78 0.032 0.35 3.06
DBSM 3843 2012 1668 0.52 0.83 1.15 10.8 52.3
DBAD 1253 691 537 0.55 0.78 2.93 15.8 54.7
BIOFOC 10,000 167 49 0.02 0.35 1.00 3.10 8.34
aM = number of compounds, N = number of Level 1 scaﬀolds, Ns =
numberofsingletonscaﬀolds,Pn=percentageofscaﬀoldsthatrepresent
n percent of compounds.
Table 4. Percentage of Compounds in Each Data Set That
Have Less than One Ring
data set number of rings = 1 N/M (Murcko) N/M (Level 1)
ICRSC 5.0% 0.41 0.16
VC 2.5% 0.20 0.04
ICRFL 12.5% 0.47 0.43
CHEMBL 6.8% 0.29 0.13
DBSM 19.4% 0.54 0.52
DBAD 15.6% 0.57 0.55
BIOFOC 0.1% 0.25 0.022180 dx.doi.org/10.1021/ci2001428 |J. Chem. Inf. Model. 2011, 51, 2174–2185
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also levels oﬀ later than for the other data sets due to the lower
proportion of singletons in the data set.
The CSFP for the Murcko framework representations
(Figure 4) indicates similar overall trends to the CSFP analysis
using Level 1 scaﬀolds, i.e. the DBAD, DBSM, and ICRFL data
setsaremoreevenlydistributedthantheVC,ICRSC,CHEMBL,
and BIOFOC data sets. However, the Murcko framework CSFP
analysisislessdiscriminatorybetweendatasets.Weproposethat
this is a result of the more granular Murcko scaﬀold deﬁnition
(i.e. they carry greater chemical description) which enhances the
apparentscaﬀolddiversitywithrespecttouseofLevel1scaﬀolds.
The information obtained from the CSFPs can be quantiﬁed
usingPnvalues;thisisthepercentageofscaﬀoldsthatrepresentn
percentofcompounds.ThesevaluesareshowninTables2and3.
The Pn values reﬂect the conclusions discussed above. For
example VC has a low proportion of Level 1 scaﬀolds and is
unevenly distributed in the CSFP; its P25, P50, and P75 values are
2.5010
2,0.13,and0.70,respectively.Thisindicatesthat75%
of the data set is represented by 0.70% of unique scaﬀolds and
conﬁrms that the data set is unevenly distributed with the
majority of compounds represented by an extremely small
proportion of scaﬀolds. The BIOFOC data set has the lowest
proportion of scaﬀolds of all the data sets, but the proportion of
singletons and the CSFP analysis indicates that molecules are
distributed more evenly over these few scaﬀolds. The P25, P50,
andP75forBIOFOCare1.00,3.10,and8.34,respectively.These
values are higher than those for other data sets with low M/N
supporting our evidence that BIOFOC is more evenly distrib-
uted over scaﬀolds.
Murcko Frameworks vs Level 1 Scaffold Tree Analyses.
From theseanalysesseveral differencesareapparentintheuseof
Level 1 scaffolds and Murcko frameworks to characterize the
scaffold diversity of chemical libraries. Murcko frameworks
deliver a more even distribution of compounds over scaffolds.
We propose that this is because Murcko frameworks are more
granular in definition (i.e. they carry greater structural descrip-
tion) such thatthere aremore unique scaffoldsinadataset. This
can be a drawback, for example, larger molecules with many ring
systems will likely have a Murcko framework similar to the
original molecule which does not represent the molecular core
(Figure 5a). However, for libraries of fragmentlike molecules
containing only one ring, many compounds will be represented
Figure 4. Murcko framework analysis: cumulative scaﬀold frequency
plot showing the distribution of compounds over Murcko framework
scaﬀolds in the ICRSC, VC, ICRFL, CHEMBL, DBSM, DBAD, and
BIOFOC data sets.
Figure 5. Examples of how compounds of diﬀerent complexity are
representedbyMurckoframeworksandLevel1scaﬀolds.Eachmolecule
had n+1 Levels numbered sequentially from Level 0 (the single
remaining ring) up to Level n (the whole molecule) where Level n-1
is the Murcko framework: compound a: A typical leadlike/druglike
chemical structure; compound b: A typical fragmentlike chemical
structure.
Figure 3. Scaﬀold Tree analysis: cumulative scaﬀold frequency plot
showing the distribution of compounds over Level 1 scaﬀolds in the
ICRSC,VC,ICRFL,CHEMBL,DBSM,DBAD,andBIOFOCdatasets.2181 dx.doi.org/10.1021/ci2001428 |J. Chem. Inf. Model. 2011, 51, 2174–2185
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Figure6. ExampleTreeMap.Thecoloredcirclesrepresentscaﬀoldsandarelabeledwiththeirscaﬀoldfrequency.Theareaandcolorofthecirclesrelate
to the scaﬀold frequency. Scaﬀold circles are grouped into gray circles if the scaﬀolds are in the same cluster.
Figure7. TreeMapoftheVCdatasetLevel1scaﬀolds.Scaﬀoldsarerepresentedbycoloredcircles,theareaandcolorofthecirclesrelatetothescaﬀold
frequency, gray circles represent clusters of scaﬀolds. Tree Maps illustrate the large proportion of singleton scaﬀolds in the data sets (many small white
circles) and the presence of highly populated scaﬀolds (few large green circles).2182 dx.doi.org/10.1021/ci2001428 |J. Chem. Inf. Model. 2011, 51, 2174–2185
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by a single common scaffold in the Murcko framework
(Figure 5b). Level 1 scaffolds perform better in both these
scenarios. Larger compounds are reduced to two ring scaffolds,
which better represent the core of the molecule (Figure 5a), while
fragments with one ring retain greater structural information
(Figure 5b). In addition, we show that Level 1 scaffolds better
highlighttheseparationbetweenmoreand lessscaffold diversedata
sets. We therefore used Level 1 scaffolds for our further analyses.
Tree Maps. We have presented the scaffold diversity of
compound libraries using the distribution of molecules over
scaffolds. This is different from structural diversity, a term which
we use here to describe differences in overall chemical structure.
Our analysis shows that the compound libraries we studied are
unevenly distributed over scaffolds; however, the well repre-
sented scaffolds may be structurally diverse. To examine this
aspectofscaffold diversitywevisualizethestructuralsimilarityof
scaffolds using Tree Maps.
28,38
The Level 1 scaﬀolds for each data set were clustered by their
ﬁngerprint similarity using FCFP_2 ﬁngerprints. The scaﬀolds
were then visualized using Tree Maps.
38 Figure 6 shows a simple
example of a Tree Map, each colored circle represents a scaﬀold,
the scaﬀold circles are grouped into gray circles which represent
the clustertowhichthescaﬀolds belong.Theareaof eachscaﬀold
circle is proportional to the scaﬀold frequency, the largest circles
have the highest scaﬀold frequency, and the smallest circles have
thelowestscaﬀoldfrequency.Thecolorofthecircleisalsorelated
tothescaﬀoldfrequency.Intheexampleeachcircleislabeledwith
the scaﬀold frequency to illustrate how the size and color of the
circles relate to scaﬀold frequency, although the actual Tree Maps
are too complex to show these numerical labels.
Tree Map representations of the Level 1 scaﬀolds forthe chemical
libraries under study are depicted in Figures 79a n dS 1 S4. Tree
Maps illustrate the large proportion of singleton scaﬀolds in the data
sets (many small white circles) and the presence of highly populated
scaﬀolds (few large green circles). The added information of the
scaﬀold clusters better depicts the structural diversity of the highly
populatedscaﬀolds.Forexample,theBIOFOCdatasetisdesignedto
contain kinase inhibitor-like compounds, and the hinge binding
scaﬀold is often highly conserved in inhibitors of this gene family.
This is illustrated in the Tree Map for the BIOFOC data set
(Figure 9) where the most highly populated scaﬀolds are clustered
together. The DBAD and DBSM data sets (Figures S4 and 8) are
morediverse,consistentwithourpreviousanalyses,herescaﬀoldsare
more evenly represented, and the most popular scaﬀolds are more
structurally diverse and therefore found in diﬀerent clusters. The
ICRSCandVC(FiguresS1and7) datasetsareunevenlydistributed
Figure 8. Tree Map of the DBSM data set Level 1 scaﬀolds. Scaﬀolds are represented by colored circles, the area and color of the circles relate to the
scaﬀoldfrequency,graycirclesrepresentclustersofscaﬀolds.TreeMapsillustratethelargeproportionofsingletonscaﬀoldsinthedatasets(manysmall
white circles) and the presence of highly populated scaﬀolds (few large green circles).2183 dx.doi.org/10.1021/ci2001428 |J. Chem. Inf. Model. 2011, 51, 2174–2185
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over scaﬀold space; however, the highly populated scaﬀolds are in
diﬀerent clusters of the Tree Map indicative of structural diversity
within the overall library.
Insummary,wehaveusedTreeMapstovisualizethediversity
of compound libraries. We show that Tree Maps are an eﬀective
way to illustrate both the distribution and structural diversity of
chemicalscaﬀolds.The Tree Mapvisualization of thecompound
libraries under study clearly shows the presence of highly
populated scaﬀolds as well as singleton scaﬀolds and illustrates
the structural similarity of scaﬀold space.
’CONCLUSIONS
We have shown that a representative set of compound libraries
commonlyusedindrugdiscoveryarepredominantlydistributedover
a small number of highly populated scaﬀolds with a concomitantly
highnumberofsingletonscaﬀoldswhenanalyzedusingbothMurcko
frameworks and Level 1 scaﬀold deﬁnitions. High representation in
small areas of scaﬀold space is useful in libraries focused on particular
biological target classes; for example the BIOFOC kinase focused
library, where dense coverage of pharmacophore space is desired.
However, this dense coverage may also represent signiﬁcant redun-
dancy in screening collections due to over population with structu-
rally similar compounds. Poorly represented or singleton scaﬀolds
may also be problematic in screening collections; for example, hit
conﬁrmation for molecules that are single exemplars of a scaﬀold can
behamperedbythepaucityofcloseanalogsavailableforscreening.In
addition,itisoftendiﬃculttoreadilyproduceSARdatathroughrapid
screening of close analogs. Thus screening collections should ideally
be diversiﬁed by inclusion of more representative exemplars of
singleton scaﬀolds.
WefoundthatLevel1scaﬀoldsbetterhighlightthediﬀerences
between compound data sets than Murcko frameworks. Analysis
using Murcko frameworks shows that data sets are more evenly
distributed over scaﬀolds then analysis using Level 1 scaﬀolds.
We propose that this diﬀerence arises because Murcko frame-
works are a more granular representation of a molecule than
Level 1 scaﬀolds (by virtue of the fact that Murcko frameworks
incorporate substituents), and, therefore, data sets appear to
containmoreuniquescaﬀolds,andappearmorediverse,thanthe
analysis by Level 1 scaﬀolds described here. Level 1 scaﬀolds are
also applicable across a wider range of molecular weight and
complexity than Murcko frameworks; for example, they encom-
pass substituents present on single ring fragmentlike molecules
which are increasingly important and prevalent constituents of
compound libraries. Level 1 scaﬀolds provide a useful compro-
mise between the minimalistic Level 0 single ring scaﬀold
representation and the more granular Murcko deﬁnition. For
these reasons we propose that Level 1 scaﬀolds are better suited
to the analysis and cross comparison of diverse compound
libraries ranging from fragmentlike and leadlike to Rule of Five
compliant.
For the ﬁrst time, we have used Tree Maps to visualize
compound library composition and show that they are an
eﬀective way of illustrating both the distribution and structural
diversity of chemical scaﬀolds. Tree Map visualization of the
compound libraries under study clearly shows the presence of
highly populated scaﬀolds as well as singleton scaﬀolds. In
addition, Tree Maps clearly illustrate the structural similarity of
constituent scaﬀolds. Tree Maps therefore provide a useful tool
formedicinalchemiststoassessthescaﬀolddiversityofscreening
Figure 9. Tree Map ofthe BIOFOC data set Level 1scaﬀolds. Scaﬀolds are represented bycolored circles, thearea and color ofthe circles relate to the
scaﬀoldfrequency,graycirclesrepresentclustersofscaﬀolds.TreeMapsillustratethelargeproportionofsingletonscaﬀoldsinthedatasets(manysmall
white circles) and the presence of highly populated scaﬀolds (few large green circles).2184 dx.doi.org/10.1021/ci2001428 |J. Chem. Inf. Model. 2011, 51, 2174–2185
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libraries, assisting the prioritization of synthetic eﬀorts directed
toward library diversiﬁcation. We are currently developing other
methods for eﬀectively visualizing and comparing scaﬀold dis-
tribution and diversity for the analysis and design of compound
libraries for hit generation.
’ASSOCIATED CONTENT
b S Supporting Information. Tree Map representations of
the ICRSC, ICRFL, CHEMBL, and DBAD data set Level 1
scaﬀoldsareshowninFiguresS1S4,respectively.Thismaterial
is available free of charge via the Internet at http://pubs.acs.org.
’AUTHOR INFORMATION
Corresponding Author
*E-mail: nathan.brown@icr.ac.uk (N.B.), julian.blagg@
icr.ac.uk (J.B.).
’ACKNOWLEDGMENT
Sarah Langdon is funded by the Institute of Cancer Research;
Nathan Brown and Julian Blagg are funded by Cancer Research
UK Grant No. C309/A8274.
We would like to thank the following: Guido Kirsten from
the Chemical Computing Group for providing the SVL script
used to produce the Scaﬀold Tree and Mike Cherry and Willem
van Hoorn from Accelrys for their valuable discussion and
solutions to the order dependency of clustering in Pipeline Pilot.
We would also like to thank Berry Matijssen, Caterina Barillari,
Ian Collins, Swen Hoelder, and Bissan Al-Lazikani for helpful
discussions.
’REFERENCES
(1) Villar, H. O.; Hansen, M. R. Design of chemical libraries for
screening. Expert Opin. Drug Discovery 2009, 4, 1215–1220.
(2) Akritopoulou-Zane,I.;Hajduk,P.J.Kinase-targetedlibraries:The
designandsynthesisofnovel,potent,andselectivekinaseinhibitors.Drug
Discovery Today 2009, 14,2 9 1 –297.
(3) Markush, E. A. Pyrazolone dye and process of making the same,
PharmaChemicalCorp, PatentNumber: 1506316, UnitedStates.1924.
The patent describes the Markush structure as “The yellow coloring
matter which may be obtained by coupling to halogen-substitution
products of pyrazolone, a diazotized unsulphonated material selected
from the groupconsisting ofaniline, homologues of aniline and halogen
substitution products of aniline”.
(4) Leach, A. R.; Gillet, V. J. An Introduction to Chemoinformatics,
Revised ed.; Springer: Dordrecht, 2007.
(5) Brough, P. A; Aherne, A.; Barril, X.; Borgognoni, J.; Boxall, K.;
Cansﬁeld,J.E.;Cheung,K.-M.J.;Collins,I.;Davies,N.G.M.;Drysdale,
M. J.; Dymock, B.; Eccles, S. A.; Finich, H.; Fink, A.; Hayes, A; Howes,
R.; Hubbard, R. E.; James, K.; Jordan, A. M.; Lockie, A.; Martins, V.;
Massey, A.; Matthews, T. P.; McDonald, E.; Northﬁeld, C. J.; Pearl,
L. H.; Prodromou, C.; Ray, S.; Raynaud, F. I.; Roughley, S. D.; Sharp,
S.Y.;Surgenor,A.;Walmsley,D.L.;Webb,P.;Wood,M.;Workman,P.;
Wright, L. 4, 5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential
Therapeutic Agents for the Treatment of Cancer. J. Med. Chem. 2008,
51, 196–218.
(6) Drysdale,M.J.;Dymock,B.M.;Finch,B.;Webb,P.;McDonald,
E.; James, K. E.; Cheung, K.; Matthews, T. Isoxazole Compounds as
InhibitorsofHeatShockProteins,PatentNumber:US2006/0241106A1,
United States, 2006.
(7) Langdon,S.R.;Ertl,P.;Brown,N.BioisostericReplacementand
Scaﬀold Hopping in Lead Generation and Optimization. Mol. Inf. 2010,
29, 366–385.
(8) Bemis,G.W.;Murcko,M.A.ThePropertiesofKnownDrugs.1.
Molecular Frameworks. J. Med. Chem. 1996, 39, 2887–2893.
(9) Nicolaou, C. A.; Tamura, S. Y.; Kelley, B. P.; Bassett, S. I.; Nutt,
R. F. Analysis of Large Screening Data Sets via Adaptively Grown
Phylogenetic-LikeTrees.J.Chem.Inf.Comput.Sci.2002,42,1069–1079.
(10) Lewell, X. Q.; Jones, A. C.; Bruce, C. L.; Harper, G.; Jones,
M. M.; Mclay, I. M.; Bradshaw, J. Drug Rings Database with Web
Interface. A Tool for Identifying Alternative Chemical Rings in Lead
Discovery Programs. J. Med. Chem. 2003, 46, 3257–3274.
(11) Kho, R.; Hodges, J. A.; Hansen, M. R.; Villar, H. O. Ring
SystemsinMutagenicityDatabases.J.Med.Chem.2005,48,6671–6678.
(12) Wilkes, S. J.; Janes, J.; Su, A. I. HierS: Hierarchical Scaﬀold
Clustering Using Topological Chemical Graphs. J. Med. Chem. 2005,
48, 3182–3193.
(13) Schuﬀenhauer, A.; Ertl, P.; Roggo, S.; Wetzel, S.; Koch, M. A.;
Waldmann, H. The Scaﬀold Tree  Visualization of the Scaﬀold Universe
by Hierarchical Scaﬀold Classiﬁcation. J. Chem. Inf. Model. 2007,47,4 7 –58.
(14) Renner,S.;vanOtterlo,W.A.L.;Seoane,M.D.;M€ ocklinghoﬀ,S.;
Hofmann,B.;Wetzel,S.;Schuﬀenhauer,A.;Ertl,P.;Oprea,T.I.;Steinhilber,
D.;Brunsveld,L.;Rauh,D .;Waldmann ,H.Bioactivity-guidedmappingand
navigation of chemical space. Nat. Chem. Biol. 2009, 5,5 8 5 –592.
(15) Clark,A.M.;Labute,P.DetectionandAssignmentofCommon
Scaﬀolds in Project Databases of Lead Molecules. J. Med. Chem. 2009,
52, 469–483.
(16) Wetzel,S.;Klein,K.;Renner,S.;Rauh,D.;Oprea,T.I.;Mutzel,
P.;Waldmann,H.InteractiveexplorationofchemicalspacewithScaﬀold
Hunter. Nat. Chem. Biol. 2009, 5, 581–583.
(17) Agraﬁotis, D. K.; Wiener, J. J. M. Scaﬀold Explorer: An
Interactive Tool for Organizing and Mining Structure-Activity Data
Spanning Multiple Chemotypes. J. Med. Chem. 2010, 53, 5002–5011.
(18) Lipkus, A. H.; Yuan, Q.; Lucas, K. A.; Funk, S. A.; Bartelt, W. F.;
Schenck, R. J.; Trippe, A. J. Structural Diversity of Organic Chemistry.
AS c a ﬀold Analysis of the CAS Registry. J. Org. Chem. 2008, 73, 4443–4451.
(19) Lameijer, E.-W.; Kok, J. N.; B€ ack, T.; IJzerman, A. P. Mining
a Chemical Database for Fragment Co-occurrence: Discovery of
“Chemical Clich  es”. J. Chem. Inf. Model. 2006, 46, 553–562.
(20) Lipkus, A. H. Exploring Chemical Rings in a Simple Topolo-
gical-Descriptor Space. J. Chem. Inf. Comput. Sci. 2001, 41, 430–438.
(21) Wester,M.J.;Pollock,S.N.;Coutsias,E.A.;Allu,T.K.;Muresan,
S.; Oprea, T. I. Scaﬀold Topologies. 2. Analysis of Chemical Databases.
J. Chem. Inf. Model. 2008, 48,1 3 1 1 –1324.
(22) Ertl, P.; Jelfs, S.; M€ uhlbacher, J.; Schuﬀenhauer, A.; Selzer, P.
Quest for the Rings: In Silico Exploration of Ring Universe To Identify
Novel Bioactive Heteroaromatic Scaﬀolds. J. Med. Chem. 2006,
49, 4568–4573.
(23) Krier, M.; Bret, G.; Rognan, D. Assessing the Scaﬀold Diversity
of Screening Libraries. J. Chem. Inf. Model. 2006, 46, 512–524.
(24) Hu, Y.; Wassermann, A. M.; Lounkine, E.; Bajorath, J. Sys-
tematic Analysis of Public Domain Compound Potency Data Identiﬁes
Selective Molecular Scaﬀolds Across Druggable Target Families. J. Med.
Chem. 2010, 53, 752–758.
(25) Grabowski, K.; Baringhaus, K.-H.; Schneider, G. Scaﬀold diver-
sity of natural products: inspiration for combinatorial library design. Nat.
Prod. Rep. 2008, 25,8 9 2 –904.
(26) Medina-Franco, J. L.; Martinez-Mayorga, K.; Bender, A.; Scior,
T. Scaﬀold Diversity Analysis of Compounds Data Sets Using an
Entropy-Based Measure. QSAR Comb. Sci. 2009, 1112, 1551–1560.
(27) Pitt, W. R.; Parry, D. M.; Perry, B. G.; Groom, C. R. Hetero-
aromatic Rings of the Future. J. Med. Chem. 2009, 52, 2952–2963.
(28) Clarke, A. 2D Depiction of Fragment Hierarchies. J. Chem. Inf.
Model. 2010, 50,3 7 –46.
(29) Ghose,A.K.;Crippen,G.M.AtomicPhysicochemicalParameters
for Three-Dimensional Structure-Directed Quantitative Structure-Activity
Relationships I. Partition Coeﬃcients as a Measure of Hydrophobicity.
J. Comput. Chem. 1986, 7,5 6 5 –577.2185 dx.doi.org/10.1021/ci2001428 |J. Chem. Inf. Model. 2011, 51, 2174–2185
Journal of Chemical Information and Modeling ARTICLE
(30) EBI-ChEMBL. https://www.ebi.ac.uk/chembldb/index.php/
group (accessed March 25, 2011).
(31) ChEMBL_03, ChEMBL-EBI. http://www.ebi.ac.uk/chembldb/
index.php (accessed May 14, 2010).
(32) Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.;
Tzur, D.; Gautam, B.; Hassanali, M. DrugBank: a knowledgebase for drugs,
drug actions and drug targets. Nucleic Acids Res. 2008, 36, D901–D906.
(33) Wishart, D. S.; Knox, C.; Guo, A. C.; Shrivastav, S.; Hassanali,
M.; Stothard, P.; Chang, Z.; Woolsey, J. DrugBank: a comprehensive
resource for in silico drug discovery and exploration. Nucleic Acids Res.
2006, 34, D668–D672.
(34) DrugBank. http://www.drugbank.ca/downloads (accessed May
14, 2010).
(35) BioFocus. http://www.biofocus.com (accessed March 25,
2011).
(36) PipelinePilot7.0;Accelrys:SanDiego,CA,USA.http://accelrys.
com/ (accessed March 25, 2011).
(37) MOE 2009.10; Chemical Computing Group: Montreal, Que-
bec, Canada. http://www.chemcomp.com/ (accessed March 25, 2011).
(38) Shneiderman, B. Tree visualization with tree-maps: 2-d space-
ﬁlling approach. ACM T. Graphic 1992, 11,9 2 –99.
(39) Kibbey, C.; Calvet, A. Molecular Property eXplorer: A Novel
Approach to Visualizing SAR Using Tree-Maps and Heatmaps. J. Chem.
Inf. Model. 2005, 45, 523–532.
(40) TreeMap v. 1.9.21; Macrofocus. http://www.macrofocus.com/
public/products/treemap/ (accessed March 25, 2011).
(41) Kelley,L.A.;Gardner,S.P.;Sutcliﬀe,M.J.Anautomatedapproach
for clustering an ensemble of NMR-derived protein structures into
conformationally related subfamilies. Protein Eng. 1996, 9, 1063–1065.
(42) Schuﬀenhauer, A.; Brown, N.; Ertl, P.; Jenkins, J. L.; Selzer, P.;
Hamon, J. Clustering and Rule-Based Classiﬁcations of Chemical
StructuresEvaluatedintheBiologicalActivitySpace.J.Chem.Inf.Model.
2007, 47, 325–336.